Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week results from BE HEARD I&II
media
posted on 2025-07-01, 12:47 authored by Adis Journals on behalf of, Vivian Shi, John Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman, Martina Porter, Koremasa Hayama, Linnea Thorlacius, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert Rolleri, Jacek Szepietowski<p dir="ltr"><b>Article full text.</b> The above Graphical Abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).</p>
